U.S. health regulator authorizes Sobi's COVID drug

(Reuters) - Sobi North America, the North American unit of Swedish Orphan Biovitrum AB, said on Thursday the U.S. Food and Drug Administration authorized its arthritis drug, Kineret, for treating COVID-19 related pneumonia.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Shinjini Ganguli)